# Anacor Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anacor-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Palo Alto, US
- Website: www.anacor.com
- Total disclosed funding: $82M
- Latest round: Series E (Jan 6, 2009)
- Investors on record: 7

## About

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapies and treatments, particularly in the field of dermatology, leveraging proprietary technology to address unmet medical needs.Founded in 2002, Anacor Pharmaceuticals, Inc. specializes in developing innovative treatments, particularly for dermatological conditions. The company has not publicly reported any significant changes in its business operations or strategy. It is based in Palo Alto, US. Notably, in November 2010, Anacor raised USD 70 million through its IPO by selling 14 million shares at USD 5.00 per share. The latest funding round was a Venture Debt round, raising USD 45.00 mn from Hercules Capital, contributing to a total amount raised of USD 24.00 mn over its history.Anacor Pharmaceuticals, Inc. focuses on developing innovative therapies primarily for dermatological conditions. Their product offerings include topical treatments that utilize their proprietary technology platform, aiming to provide effective solutions for skin disorders. Their products are used by healthcare professionals in various healthcare settings, including hospitals and outpatient clinics.In the most recent year of 2015, Anacor Pharmaceuticals, Inc. reported a revenue of USD 82.36 mn and an EBITDA of USD -54.53 mn.Anacor Pharmaceuticals, Inc. is strategically focused on advancing its pipeline of dermatological treatments, with plans to launch new products in the upcoming years. The company aims to expand its market presence, targeting both North America and Europe by 2022. The funds raised from the most recent Venture Debt round will support these initiatives, enabling the development and commercialization of innovative products that address dermatological needs.

## Funding rounds

- Series E, Jan 6, 2009, $50M — Care Capital, RHO, Aberdare Ventures, Venrock, GlaxoSmithKline, Schering-Plough Corporation
- Series C, May 11, 2005, $25M — Care Capital, RHO, Aberdare Ventures, Venrock, Red Abbey
- Series A, Oct 29, 2002, $4M — RHO, Aberdare Ventures
- Series A, Apr 1, 2002, $3M — RHO, Aberdare Ventures

## Investors

- RHO (https://capitalatlas.ai/funds/rho) — Series A, Series C, Series E
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A, Series C, Series E
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series C, Series E
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C, Series E
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series C
- GlaxoSmithKline — Series E
- Schering-Plough Corporation — Series E